Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
I (Alex Cook, part of Primes newsroom team) connected with Ben Urick, PharmD, senior director of health outcomes, and Landon Marshall, PharmD, health outcomes research principal, who presented at the conference and serve as authors on the latest cost-of-care research to learn more about the studies and their experience at the conference
In fact, there are reports which demonstrate that administration of both a probiotic microorganism strain and prebiotics influences GLP-1 release and signaling
The pilot program is temporary, and eligibility is based on BMI and other clinical criteria
While topical creams with peptides can offer some surface-level benefits, injectable peptides provide a much more profound and lasting effect by working from the inside out
